TME Pharma N.V. · EURONEXT:ALTME
TME Pharma — NOXXON Pharma — Shareholder Meeting (June 2021)
32 slides from TME Pharma's shareholder meeting presentation, Jun 24, 2021
Slide 1: Annual Shareholder's Meeting
Annual Shareholder’s Meeting 24 June 2021 May 12021 © NOXXON Pharma
Slide 2: Agenda
AGENDA 1. Opening 2. Annual Accounts 2020 a. Discussion of the annual report 2020 (discussion) b. Discussion of Application of the remuneration for members of the board of directors (discussion) c. Policy on additions to reserves and on dividends (discussion) d. Adoption of the annual accounts 2020
Slide 3: Agenda
AGENDA 4. Appointment of members of the supervisory board (voting) a. Appointment of Susan Coles as member of the supervisory board (voting) Voting results: b. b. Appointment of Dr. Martine van Vugt as member of the supervisory board (voting) all unanimously approved c. c. Appointment of Gregory Wea
Slide 4: Agenda
AGENDA 9. Renewal delegation to the board of directors to acquire shares (voting) Voting results: unanimously approved 10. Change of the remuneration in the form of shares and rights to subscribe for shares for the members of the board of directors and the supervisory board (voting) Voting results:
Slide 5: Agenda item 2a: Discussion of the annual report 2020
AGENDA ITEM 2a. Discussion of the annual report 2020 (discussion) 5
Slide 6: Pipeline Assets Complement Anti-Cancer Therapies to Enhance their Therapeutic Efficacy
AGENDA ITEM 2a. Pipeline Assets Complement Anti-Cancer Therapies to Enhance their Therapeutic Efficacy Next Inflection Partner/ Indication Preclinical Phase 1/2 Phase 2 Phase 3 Point Collaborator Scientific NOX-A12 + Immunotherapy Phase 2 read-out Collaborator Pancreatic Cancer H2 2023 NOX-A12 + Rad
Slide 7: Highlights 2020 & Subsequent Events: NOX-A12 + Radiotherapy
AGENDA ITEM 2a. HIGHLIGHTS 2020 & Subsequent Events ▪ NOX-A12 + Radiotherapy Clinical Trial in First Line Brain Cancer Patients - Throughout 2020 and to date, NOXXON has successfully advanced its Phase 1/2 dose-escalation study of NOX-A12 in first-line brain cancer patients in combination with radio
Slide 8: Highlights 2020 & Subsequent Events: NOX-A12 + Immunotherapy
AGENDA ITEM 2a. HIGHLIGHTS 2020 & Subsequent Events ▪ NOX-A12 + Immunotherapy Clinical Trial in Heavily Pre-Treated Metastatic Pancreatic and Colorectal Cancer Patients - In 2020, NOXXON completed the clinical trial of the combination of NOX-A12 with Keytruda® in heavily pre- treated metastatic micr
Slide 9: Highlights 2020 & Subsequent Events: SAB, Manufacturing, COVID-19
AGENDA ITEM 2a. HIGHLIGHTS 2020 & Subsequent Events ▪ Scientific Advisory Board (SAB) - In February 2021, NOXXON appointed a Scientific Advisory Board (SAB) under the chairmanship of Dr. Jose Saro. - The SAB includes four leading pancreatic cancer experts: Dr. Elena Gabriela Chiorean, Dr. Eileen M.
Slide 10: Highlights: Strong Cash Position on December 31, 2020
AGENDA ITEM 2a. HIGHLIGHTS 2020 & Subsequent Events ▪ Strong Cash Position on December 31, 2020 - On December 31, 2020, NOXXON had cash resources of €10.3 million. - The company successfully raised €14.5 million in cash in 2020 through multiple private placements, exercises of outstanding warrants t
Slide 11: Highlights 2020
AGENDA ITEM 2a. HIGHLIGHTS 2020 ▪ Consolidated financial statements 2020 - Cash and cash equivalents on balance sheet date of € 10.3 million (prior year: € 1.4 million) - Net loss of € 10.4 million (compared to € 0.9 million in 2019), with loss from operations K€ 5.8 million (prior year: K€ 3.9 mill
Slide 12: Consolidated Statements of Comprehensive Loss
AGENDA ITEM 2a. Consolidated Statements of Comprehensive loss Remarks • In 2020, other operating income decreased on (in K€) 2020 2019 an overall basis compared to 2019 and results Other operating income 147 279 from sale of raw materials and services Research and development expenses -4,017 -2,108
Slide 13: Consolidated Statements of Financial Position
AGENDA ITEM 2a. Consolidated Statements of Financial Position Remarks • The movements in total current assets from 31 December (in K€) 2020 2019 2019 to 31 December 2020 primarily relate to an increase Intangible assets 4 4 in cash and cash equivalents by K€ 8,919 from K€ 1,385 to Equipment 52 30 K€
Slide 14: Consolidated Cash-Flow Statements
AGENDA ITEM 2a. Consolidated Cash-Flow Statements Remarks • The increase in net cash used in operating activities (in K€ ) 2020 2019 from K€ 4,286 in 2019 to K€ 5,224 in 2020 is mainly a result Net cash used in operating activities -5,224 -4,286 of the increase in the loss from operations, partly of
Slide 15: NOXXON Investment Highlights
NOXXON Investment Highlights Clinical stage Expert in Tumor Focus on 2 large orphan Robust Upcoming biotech Microenvironment cancer indications commercial Catalysts company protection ~$6.5bn Addressable Market Mission to improve In brain cancer (1st line GBM) Q4 2021 cancer treatment and pancreatic
Slide 16: Agenda item 2b: Remuneration of the board of directors
AGENDA ITEM 2b. Application of the remuneration of the members of the board of directors (discussion) 16
Slide 17: Agenda item 2c: Policy on reserves and dividends
AGENDA ITEM 2c. Policy on additions to reserves and on dividends (discussion) 17
Slide 18: Agenda item 2d: Adoption of the annual accounts 2020
AGENDA ITEM 2d. Adoption of the annual accounts 2020 (voting) 18
Slide 19: Agenda item 2e: Release from liability of the board of directors
AGENDA ITEM 2e. Release from liability of the sole member of the board of directors (voting) 19
Slide 20: Agenda item 2f: Release from liability of the supervisory board
AGENDA ITEM 2f. Release from liability of the members of the supervisory board (voting) 20
Slide 21: Agenda item 3: Re-appointment of Dr. A. Mangasarian
AGENDA ITEM 3. Re-appointment of Dr. A. Mangasarian as member of the board of directors (voting) 21
Slide 22: Agenda item 4: Appointment of supervisory board members
AGENDA ITEM 4. Appointment of members of the supervisory board (voting) a. Appointment of Susan Coles as member of the supervisory board (voting) b. Appointment of Dr. Martine van Vugt as member of the supervisory board (voting) c. Appointment of Gregory Weaver as member of the supervisory board (vo
Slide 23: Agenda item 5: Appointment of statutory auditor
AGENDA ITEM 5. Appointment of Baker Tilly (Netherlands) N.V. as statutory auditor for the financial year 2021 (voting) 23
Slide 24: Agenda item 6: Amendment of articles, authorised share capital
AGENDA ITEM 6 Partial amendment of the articles of association in relation to the increase of authorised share capital (voting) 24
Slide 25: Agenda item 7: Transitional provision, authorised share capital
AGENDA ITEM 7. Partial amendment of the articles of association in relation to introducing a transitional provision to increase the authorised share capital (voting) 25
Slide 26: Agenda item 8: Delegation to issue ordinary shares
AGENDA ITEM 8. Delegation to the board of directors to issue ordinary shares and to limit or exclude any pre-emptive rights in connection therewith (voting) 26
Slide 27: Agenda item 9: Renewal delegation to acquire shares
AGENDA ITEM 9. Renewal delegation to the board of directors to acquire shares (voting) 27
Slide 28: Agenda item 10: Change of remuneration in shares
AGENDA ITEM 10. Change of the remuneration in the form of shares and rights to subscribe for shares for the members of the board of directors and the supervisory board (voting) 28
Slide 29: Agenda item 11: Amendment of Remuneration Policy Sec. 3.4
AGENDA ITEM 11. Amendment of Sec. 3.4 of the Remuneration Policy regarding the compensation structure of non-executive directors in relation to grant of options (voting) 29
Slide 30: Agenda item 12: Amendment of Remuneration Policy Sec. 3.6
AGENDA ITEM 12. Amendment of Sec. 3.6 of the Remuneration Policy regarding the compensation for membership of a committee (voting) 30
Slide 31: Agenda item 13: Close of meeting
AGENDA ITEM 13. CLOSE OF MEETING 31
Slide 32: Thank you!
Thank you! 32